AOCI at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's AOCI?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported AOCI of -$665K in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's AOCI changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's AOCI decreased by 303.0% year-over-year, from -$165K to -$665K.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's AOCI?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's AOCI has grown at a -6.0% compound annual growth rate (CAGR), from -$34K to -$25K.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.